Ionis Pharmaceuticals Inc (IONS) KPIs and segments
Close on Nov 13, 2026Market cap $4.83BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Ionis Pharmaceuticals's business
Ionis Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Research and Development Revenue($M) | 149 | 138 | 62.0 | 41.1 | 349 | 55.4 | 141 | 58.1 | 153 | 59.9 | 246 | 60.1 | |
Collaborative Agreement Revenue($M) | 133 | 121 | 52.4 | 31.4 | 337 | 45.0 | 96.9 | 44.9 | 142 | 49.3 | 179 | 44.2 | |
Commercial Revenue($M) | 119 | 108 | 141 | 116 | 103 | 76.2 | 85.7 | 75.7 | 72.0 | 59.6 | 78.8 | 84.1 | |
Royalty Revenue($M) | 76.0 | 58.3 | 75.7 | 75.7 | 70.0 | 64.2 | 77.3 | 66.8 | 63.8 | 49.4 | |||
SPINRAZA Royalties($M) | 53.5 | 43.7 | 54.0 | 55.9 | 54.3 | 48.0 | 63.7 | 57.2 | 56.7 | 38.5 | 61.9 | 67.3 | |
Product Sales, Net($M) | 31.1 | 43.0 | 58.0 | 31.8 | 19.3 | 6.29 | 0 | 0 | 0 | 0 | 9.49 | 8.29 | |
DAWNZERA Sales, Net($M) | 26.6 | 15.9 | 0 | 0 | |||||||||
WAINUA Royalties($M) | 16.4 | 10.7 | 16.0 | 13.3 | 10.4 | 9.37 | 9.93 | 5.37 | 3.78 | 1.13 | 0 | 0 | |
WAINUA Joint Development Revenue($M) | 16.2 | 17.6 | 9.61 | 9.69 | 12.4 | 10.4 | 44.0 | 13.2 | 11.7 | 10.6 | 66.5 | 16.0 | |
TEGSEDI and WAYLIVRA Revenue, Net($M) | 13.5 | 5.72 | 8.19 | 8.63 | |||||||||
Other Commercial Revenue($M) | 11.5 | 6.53 | 7.65 | 8.11 | 13.5 | 5.72 | 8.45 | 8.92 | 8.19 | 10.2 | 17.0 | 16.8 | |
Other Royalties($M) | 6.04 | 3.90 | 5.70 | 6.48 | 5.20 | 6.78 | 3.66 | 4.23 | 3.32 | 9.81 | |||
TRYNGOLZA Sales, Net($M) | 4.57 | 27.1 | 31.8 | 19.3 | 6.29 | 0 | 0 | 0 | |||||
Other Revenue($M) | 0 | 0 | 0 | 1.58 | |||||||||
Earlier reporting (last reported 2024)2 | |||||||||||||
Earlier reporting (last reported 2026)1 | |||||||||||||
Earlier reporting (last reported 2026)1 | |||||||||||||
29 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-07-29.
See a number that looks wrong?